Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

D
Da Silva Moura, David

INSTITUTO DE INVESTIGACIÓN SANITARIA FUNDACIÓN JIMENEZ DIAZ (IIS-FJD)
(P 38) VALIDATION OF THE SIGNIOS SEVEN-GENE SIGNATURE FOR PREDICTING ANTI-PD-1 INHIBITOR EFFICACY IN SARCOMA
David Da Silva Moura
Favorite
(P 462) HDAC INHIBITORS AS POTENTIAL SFT THERAPIES
David Da Silva Moura
Favorite
Dürr, Hans Roland

Orthopaedic Oncology, Department of Orthopaedics and Trauma Surgery, LMU University Hospital, Munich, Germany
(P 64) ATRX EXPRESSION CORRELATES WITH REDUCED IMMUNE CHECKPOINT EXPRESSION AND POOR SURVIVAL IN HIGH-RISK SOFT TISSUE SARCOMAS
Hans Roland Dürr
Favorite
(P 443) FIRST-LINE PAZOPANIB IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS
Hans Roland Dürr
Favorite
Daffinoti, Anabella

Angel H Roffo Institute of Oncology
(P 386) RADIO-GUIDED SURGERY FOR NONPALPABLE SOFT-TISSUE SARCOMAS
Anabella Daffinoti
Favorite
Dagrada, Gianpaolo

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 32) EFFECTIVENESS OF LURBINECTEDIN PLUS IRINOTECAN IN PRECLINICAL MODEL OF DESMOPLASTIC SMALL ROUND CELL TUMOR
Gianpaolo Dagrada
Favorite
Dai, Xiaoxian

Kura Oncology, Inc.
(P 423) ZIFTOMENIB IN COMBINATION WITH IMATINIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) AFTER IMATINIB FAILURE: PHASE 1A/B STUDY OF SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY
Xiaoxian Dai
Favorite
Dalal, Shivani

Memorial Healthcare System
(P 330) LEIOMYOSARCOMA IN THE REAL WORLD: RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS AT A COMMUNITY ONCOLOGY CENTER IN SOUTH FLORIDA (MEMORIAL HEALTHCARE SYSTEM)
Shivani Dalal
Favorite
(P 459) EPIDEMIOLOGICAL TRENDS, TREATMENT PATTERNS, AND SURVIVAL DISPARITIES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A SEER ANALYSIS, 2001-2020
Shivani Dalal
Favorite
Daley, Jessica

University of Pittsburgh
(P 256) THE SEAN KARL COHORT: A NATIONAL COLLABORATIVE SINGLE-CELL RNASEQ STUDY OF PAIRED PATIENT EWING SARCOMA SPECIMENS
Jessica Daley
Favorite
Dalrio, Caterina

IRCCS Rizzoli Orthopaedic Institute
(P 18) ESTABLISHMENT AND CHARACTERIZATION OF A NOVEL PRIMARY CELL LINE FROM A BONE METASTASIS OF OSTEOSARCOMA
Caterina Dalrio
Favorite
D'Amato, Gina

University of Miami Sylvester Comprehensive Cancer Center
(P 117) THERAPEUTIC POTENTIAL OF DOXORUBICIN AND DASATINIB COMBINATION IN OSTEOSARCOMA
Gina D'Amato
Favorite
(P 131) GLUCOSE TRANSPORTER 1 (GLUT1) INHIBITION DECREASES THE GROWTH AND PROLIFERATION OF CHONDROSARCOMA
Gina D'Amato
Favorite
(P 201) METASTATIC PATTERNS, TREATMENT MODALITIES, AND OVERALL SURVIVAL IN OLIGOMETASTATIC GIST: A SINGLE-CENTER RETROSPECTIVE STUDY
Gina D'Amato
Favorite
(P 217) PATIENT QUESTIONNAIRE EXPLORING THE PRE-SARCOMA DIAGNOSIS CHARACTERISTICS OF SARCOMA PATIENTS
Gina D'Amato
Favorite
(P 224) PAN-SARCOMA DATABASE (PSDB): AN UPDATE ON MIAMI'S COLLABORATIVE MULTI-USER DATA PIPELINE OF SARCOMA DATA USING REDCAP AND R CODING
Gina D'Amato
Favorite
(P 225) GLOBAL REGISTRY OF SOLITARY FIBROUS TUMORS (SFT): INTEGRATING CLINICAL, MOLECULAR, AND ENVIRONMENTAL DATA- THE HOROWITZ SFT INITIATIVE (HSFTI)
Gina D'Amato
Favorite
(P 320) CLINICAL CHARACTERISTICS AND RECURRENCE PATTERNS IN HISPANIC VS. NON-HISPANIC PATIENTS WITH LEIOMYOSARCOMA: FINDINGS FROM A RETROSPECTIVE SINGLE-CENTER COHORT STUDY
Gina D'Amato
Favorite
(P 327) INITIAL TREATMENT MODALITY AND RECURRENCE IN NON-METASTATIC LEIOMYOSARCOMA: A RETROSPECTIVE COHORT STUDY
Gina D'Amato
Favorite
(P 333) METABOLIC SYNDROME CORRELATION WITH LIPOSARCOMA INCIDENCE AND OUTCOMES: A RETROSPECTIVE ANALYSIS.
Gina D'Amato
Favorite
(P 362) SHOULD PAZOPANIB BE USED AS A MAINTENANCE THERAPY TO IMPROVE RECURRENCE-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WHO RECEIVED MAI IN SOFT TISSUE SARCOMA?
Gina D'Amato
Favorite
(P 369) CLINICAL CHARACTERISTICS & TREATMENT OUTCOME PATTERNS OF SOLITARY FIBROUS TUMORS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS
Gina D'Amato
Favorite
(P 393) DISTINCT SECONDARY MUTATIONAL LANDSCAPES ARE ASSOCIATED WITH NAB2–STAT6 FUSION BREAKPOINTS IN SOLITARY FIBROUS TUMORS
Gina D'Amato
Favorite
(P 397) EXPLORING REAL WORLD DATA OF RECURRENCE IN NON-METASTATIC MYXOFIBROSAROMA: AN UPDATED RETROSPECTIVE COHORT STUDY
Gina D'Amato
Favorite
(P 422) EFFICACY WITH VIMSELTINIB IN PATIENTS (PTS) WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AND PRIOR COLONY-STIMULATING FACTOR 1 (CSF1) INHIBITOR THERAPY: A PHASE 2 CASE SERIES
Gina D'Amato
Favorite
D'Amato, Vittoria

IRCCS Humanitas Research Hospital
(P 203) MINIMALLY INVASIVE RESECTION OF MULTIFOCAL DUODENO-JEJUNAL GISTS IN NEUROFIBROMATOSIS TYPE 1
Vittoria D'Amato
Favorite
(P 318) BURIED DE-EPITHELIALIZED FLAP RECONSTRUCTION AFTER WIDE EXCISION OF THIGH SARCOMAS: EARLY EXPERIENCE FROM A SPECIALIZED SARCOMA SURGERY UNIT
Vittoria D'Amato
Favorite
D'Amato, Vittoria

IRCCS Humanitas Research Hospotal
(P 339) POSTERIOR APPROACH FOR RADICAL RESECTION OF SACROCOCCYGEAL CHORDOMA: A SURGICAL PERSPECTIVE FROM A TERTIARY REFERRAL CENTER
Vittoria D'Amato
Favorite
D'Amato, Vittoria

IRCCS Humanitas Research Hospital
(P 365) UROLOGICAL RECONSTRUCTION DURING RETROPERITONEAL AND PELVIC SARCOMA SURGERY: EXPERIENCE FROM A HIGH-VOLUME SARCOMA CENTER
Vittoria D'Amato
Favorite
D'Ambrosio, Lorenzo

University Hospital S. Luigi Gonzaga
(P 231) INCREASED LIFETIME RISK (LTR) OF SOFT TISSUE SARCOMAS (STS) IN PATIENTS WITH LOW-RISK GASTROINTESTINAL STROMAL TUMORS (GIST): A RETROSPECTIVE ANALYSIS FROM THE ITALIAN SARCOMA GROUP (ISG)
Lorenzo D'Ambrosio
Favorite
(P 458) BETWEEN LYMPHOMAS AND SARCOMAS: A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG) ON HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN)
Lorenzo D'Ambrosio
Favorite
Dandwani, Mehndi

University of Iowa Hospitals and Clinics
(P 343) PROGRESSION FREE SURVIVAL OF IMMUNE CHECKPOINT INHIBITORS IN THE FIRST-LINE TREATMENT OF METASTATIC SARCOMA: A SINGLE CENTER RETROSPECTIVE ANALYSIS.
Mehndi Dandwani
Favorite
D'Angelo, Sandra

Memorial Sloan Kettering Cancer Center
(P 186) BRAF V600E-MUTATED GASTROINTESTINAL STROMAL TUMORS: A CASE SERIES AND ANALYSIS OF IMMUNE TUMOR INFILTRATE
Sandra D'Angelo
Favorite
(P 187) THERAPEUTIC OUTCOMES IN NF1-ALTERED GIST TREATED WITH MEK INHIBITION: A SINGLE-CENTER EXPERIENCE
Sandra D'Angelo
Favorite
(P 409) RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS INCLUDING HLA GENOTYPE IN MYXOID LIPOSARCOMA
Sandra D'Angelo
Favorite
(P 421) CHARACTERIZING THE IMMUNE RESPONSE TO INTRATUMORAL TIGILANOL TIGLATE (TT) IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS) IN A PHASE IIA TRIAL (NCT05755113)
Sandra D'Angelo
Favorite
(P 430) A PH/2 STUDY OF THE RADIOPHARMACEUTICAL [AC-225]RTX-2358 IN THE TREATMENT OF RELAPSED / REFRACTORY (R/R) SOFT TISSUE SARCOMA (STS) THE ATLAS STUDY - ACTINIUM THERAPY FOR LATE-STAGE AGGRESSIVE SARCOMAS
Sandra D'Angelo
Favorite
(P 467) TREATMENT OUTCOMES IN AGGRESSIVE ANGIOMYXOMA: A SINGLE INSTITUTION EXPERIENCE
Sandra D'Angelo
Favorite
Danieau, Geoffroy

McGill university and RI-MUHC
(P 15) EZHIP: A NOVEL EPIGENETIC DRIVER OF OSTEOSARCOMA PATHOGENESIS
Geoffroy Danieau
Favorite
Daniel, Sara

Mayo Clinic
(P 300) FEATURES AND OUTCOMES OF PATIENTS WITH GASTROINTESTINAL LEIYOMYOSARCOMA
Sara Daniel
Favorite
Daniyan, Anthony

Memorial Sloan Kettering Cancer Center
(P 237) DEVELOPMENT OF EPHA2 CAR T CELL THERAPY FOR OSTEOSARCOMA
Anthony Daniyan
Favorite
Dann, Amanda

University of Texas Southwestern Medical Center
(P 03) CONGRUENCE OF CIRCULATING TUMOR DNA & RADIOGRAPHIC RESPONSE IN BONE AND SOFT TISSUE SARCOMA
Amanda Dann
Favorite
(P 280) PERSONALIZED ULTRA-FRACTIONATED STEREOTACTIC ADAPTIVE RADIOTHERAPY (PULSAR) FOR ADULT AND PEDIATRIC SARCOMAS
Amanda Dann
Favorite
Darrow, Morgan

Pathology and Laboratory Medicine, University of California, Davis
(P 244) INTRATUMORAL TIGIT BLOCKADE AUGMENTS ANTI-TUMOR RESPONSES AND BYPASSES HYPERFUNCTIONALITY OF PERIPHERAL TIGIT+ NK CELLS IN MOUSE AND HUMAN MODELS OF BONE AND SOFT TISSUE SARCOMA
Morgan Darrow
Favorite
(P 245) SUBTYPE SPECIFIC CHARACTERIZATION OF IMMUNE INFILTRATION IN SOFT TISSE SARCOMAS
Morgan Darrow
Favorite
Darwish, Alaa

Department of Genetics, The Hebrew University of Jerusalem, Jerusalem, Israel.
(P 06) RAPID, POINT-OF-CARE DNA METHYLATION & MOLECULAR LANDSCAPE BASED SARCOMA CLASSIFICATION
Alaa Darwish
Favorite
Das, Bidisha

Brigham and Women's Hospital
(P 309) RETROPERITONEAL LIPOMAS: MULTICENTER CLINICAL EXPERIENCE WITH AN EXTREMELY RARE DISEASE ENTITY
Bidisha Das
Favorite
David, Andre

UNIFESP
(P 347) SURVIVAL ANALYSIS AND PROGNOSTIC FACTORS OF SOFT TISSUE SARCOMAS OF THE TRUNK AND EXTREMITIES TREATED BETWEEN 2010 AND 2015: EXPERIENCE OF THE BRAZILIAN NATIONAL CANCER INSTITUTE
Andre David
Favorite
David, Bruna

Grupo Oncoclinicas / Brazilian National Cancer Institute
(P 285) MULTICENTER STUDY OF SPATIALLY FRACTIONATED RADIOTHERAPY (LATTICE) FOR LARGE-VOLUME RADIORESISTANT SARCOMAS
Bruna David
Favorite
David, Clare

University College London Hospitals
(P 281) LOCAL CONTROL WITH MODERATELY HYPOFRACTIONATED DEFINITIVE RADIOTHERAPY DELIVERED WITH A SIMULTANEOUS INTEGRATED BOOST TECHNIQUE TO NON-EXTREMITY SOFT TISSUE AND BONE SARCOMAS
Clare David
Favorite
Davidorf, Oliver

Sarcoma Oncology Center
(P 388) TRIAL IN PROGRESS: A PHASE 2 STUDY OF METRONOMIC TRABECTEDIN, GEMCITIBAINE, AND DACARBAZINE IN PREVIOUSLY TREATED ADVANCED SOFT TISSUE SARCOMA (NCT04535271)
Oliver Davidorf
Favorite
Davila, Eduardo

University of Colorado School of Medicine
(P 234) DOXORUBICIN PLUS BOTENSILIMAB, A NEXT GENERATION CTLA4 INHIBITOR, WITH OR WITHOUT BALSTILIMAB, A PD1 INHIBITOR, IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMAS
Eduardo Davila
Favorite
Davis, Jessica

Riley Hospital for Children
(P 168) LEVERAGING LARGE LANGUAGE MODELS FOR STRUCTURED INFORMATION EXTRACTION FROM EWING SARCOMA PATHOLOGY REPORTS
Jessica Davis
Favorite
(P 256) THE SEAN KARL COHORT: A NATIONAL COLLABORATIVE SINGLE-CELL RNASEQ STUDY OF PAIRED PATIENT EWING SARCOMA SPECIMENS
Jessica Davis
Favorite
Davis, Lara

Knight Cancer Institute, Oregon Health & Science University
(P 315) ANALYSIS OF CHANGES IN T2-WEIGHTED SIGNAL INTENSITY AND TUMOR VOLUME AND EXPOSURE-RESPONSE IN THE RINGSIDE PHASE 2 STUDY OF VAREGACESTAT FOR DESMOID TUMORS
Lara Davis
Favorite
(P 410) SUBGROUP ANALYSIS OF THE PHASE 2 PART OF THE RINGSIDE PHASE 2/3 TRIAL OF VAREGACESTAT FOR TREATMENT OF DESMOID TUMORS
Lara Davis
Favorite
(P 416) A PHASE 2 MULTICENTER OPEN-LABEL BASKET STUDY OF TAZEMETOSTAT IN ADULT PATIENTS WITH INI1-NEGATIVE EPITHELIOID SARCOMA – FINAL ANALYSIS
Lara Davis
Favorite
Davis, Olivia

Department of Internal Medicine, University of Michigan
(P 227) TREATMENT PATTERNS IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMORS: ADDRESSING COMMUNICATION IN A NEW THERAPEUTIC LANDSCAPE
Olivia Davis
Favorite
Davison, Zoe

Bone Cancer Research Trust
(P 207) LONG-TERM FOLLOW-UP AND LATE EFECTS MONITORING FOR UK BONE SARCOMA PATIENTS: A SERVICE MAPPING EXCERCISE
Zoe Davison
Favorite
Davis, Sterenn

Adaptimmune
(P 247) SINGLE-CELL RNA SEQUENCING OF AFAMITRESGENE AUTOLEUCEL INDICATES MECHANISMS OF PERSISTENCE AND ANTI-TUMOR ACTIVITY
Sterenn Davis
Favorite
Davtyan, Ellen

Yerevan State Medical University
(P 158) GLOBAL INEQUITIES IN CHONDROSARCOMA CLINICAL TRIALS: A COMPREHENSIVE ANALYSIS ACROSS THREE DECADES
Ellen Davtyan
Favorite
Daw, Najat

MD Anderson Cancer Center
(P 47) EWSR1::WT1 FUSION ONCOPROTEIN ACTIVITY SHAPES LINEAGE HETEROGENEITY IN DESMOPLASTIC SMALL ROUND CELL TUMORS
Najat Daw
Favorite
(P 83) OUTCOMES OF MULTIMODAL PERIOPERATIVE TREATMENT IN OSTEOSARCOMAS OF THE JAW
Najat Daw
Favorite
De Bellis, Chelsea

McGill University
(P 68) MULTI-OMIC INTRA- AND INTER-TUMOR HETEROGENEITY OF BENIGN SMOOTH MUSCLE TUMORS
Chelsea De Bellis
Favorite
De Cian, Franco

IRCCS Ospedale Policlinico San Martino
(P 328) INNOVATING SARCOMA EDUCATION: EARLY OUTCOMES OF THE ITALIAN SOCIETY OF SURGICAL ONCOLOGY (SICO) SARCOMA SOCIAL MULTI-PLATFORM JOURNAL CLUB INITIATIVE
Franco De Cian
Favorite
De Cock, Lore

UZ Leuven
(P 33) THE NOVEL TRANSCRIPTIONAL INHIBITORS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Lore De Cock
Favorite
De La Cuesta, Esther

Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA
(P 417) EFFICACY AND SAFETY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS
Esther De La Cuesta
Favorite
De Luca, Ida

Azienda Ospedaliera di Cosenza
(P 458) BETWEEN LYMPHOMAS AND SARCOMAS: A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG) ON HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN)
Ida De Luca
Favorite
de Miranda, Noel

Leiden University Medical Center
(P 127) AN INTEGRATED CLINICAL GENOMIC AND TRANSCRIPTOMIC SUBGROUPING OF CENTRAL CHONDROSARCOMA
Noel de Miranda
Favorite
de Moraes, Jose Carlos

Brazilian National Cancer Institute
(P 347) SURVIVAL ANALYSIS AND PROGNOSTIC FACTORS OF SOFT TISSUE SARCOMAS OF THE TRUNK AND EXTREMITIES TREATED BETWEEN 2010 AND 2015: EXPERIENCE OF THE BRAZILIAN NATIONAL CANCER INSTITUTE
Jose Carlos de Moraes
Favorite
De Pas, Tommaso Martino

Medical Oncology Division, Cliniche Humanitas Gavazzeni, Bergamo, Italy; previously at Unit of Sarcomas and Thymomas, European Institute of Oncology, Milan
(P 231) INCREASED LIFETIME RISK (LTR) OF SOFT TISSUE SARCOMAS (STS) IN PATIENTS WITH LOW-RISK GASTROINTESTINAL STROMAL TUMORS (GIST): A RETROSPECTIVE ANALYSIS FROM THE ITALIAN SARCOMA GROUP (ISG)
Tommaso Martino De Pas
Favorite
De Sutter, Luna

UZ Leuven
(P 33) THE NOVEL TRANSCRIPTIONAL INHIBITORS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Luna De Sutter
Favorite
Deasy, Joseph

Memorial Sloan Kettering Cancer Center
(P 22) SINGLE CELL SEQUENCING ENABLES LINEAGE-INFORMED TARGETING OF OSTEOSARCOMA
Joseph Deasy
Favorite
Debruyne, Channa

Servier
(P 128) ISOCITRATE DEHYDROGENASE 1 (IDH1) MUTATION TESTING IN THE PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA (CHONQUER)
Channa Debruyne
Favorite
Degnim, Amy

Mayo Clinic
(P 246) CTLA4 PATHWAY ACTIVATION IN RADIATION-INDUCED ANGIOSARCOMA: A TRANSCRIPTOMIC RATIONALE FOR IMMUNE CHECKPOINT BLOCKADE
Amy Degnim
Favorite
Dehner, Carina

University of Pennsylvania
(P 466) PATHOGENESIS AND THERAPEUTIC TARGETS IN KERATIN-POSITIVE GIANT CELL-RICH TUMOR
Carina Dehner
Favorite
Dei Tos, Angelo Paolo

Azienda Ospedaliera di Padova
(P 231) INCREASED LIFETIME RISK (LTR) OF SOFT TISSUE SARCOMAS (STS) IN PATIENTS WITH LOW-RISK GASTROINTESTINAL STROMAL TUMORS (GIST): A RETROSPECTIVE ANALYSIS FROM THE ITALIAN SARCOMA GROUP (ISG)
Angelo Paolo Dei Tos
Favorite
(P 458) BETWEEN LYMPHOMAS AND SARCOMAS: A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG) ON HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN)
Angelo Paolo Dei Tos
Favorite
Deinzer, Christoph K. W.

Department of Internal Medicine VIII - Medical Oncology and Pneumology, University Hospital Tübingen and Center for Soft Tissue Sarcomas, GIST and Bone Tumors (ZWS) of the University Hospital Tübingen and of the Comprehensive Cancer Center (CCC) Tübingen-Stuttgart, Tübingen, Germany
(P 204) ANALYSIS OF QUALITY INDICATORS OF SOFT TISSUE SARCOMA TREATMENT WITH CANCER REGISTRY DATA IN GERMANY 2015-2021
Christoph K. W. Deinzer
Favorite
Dela Cruz, Filemon

Memorial Sloan Kettering Cancer Center
(P 08) BUILDING A MEDICAL DONATION NETWORK TO ENHANCE DEVELOPMENT OF PEDIATRIC TUMOR MODELS
Filemon Dela Cruz
Favorite
(P 22) SINGLE CELL SEQUENCING ENABLES LINEAGE-INFORMED TARGETING OF OSTEOSARCOMA
Filemon Dela Cruz
Favorite
(P 25) IDENTIFICATION AND VALIDATION OF NON-GENETICALLY ENCODED VULNERABILITIES IN EWING SARCOMA
Filemon Dela Cruz
Favorite
(P 26) DEVELOPING AN ORTHOTOPIC MODEL OF DESMOPLASTIC SMALL ROUND CELL TUMOR
Filemon Dela Cruz
Favorite
(P 48) PRECLINICAL ACTIVITY OF MEK INHIBITION IN COMBINATION WITH CHEMOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Filemon Dela Cruz
Favorite
(P 237) DEVELOPMENT OF EPHA2 CAR T CELL THERAPY FOR OSTEOSARCOMA
Filemon Dela Cruz
Favorite
(P 256) THE SEAN KARL COHORT: A NATIONAL COLLABORATIVE SINGLE-CELL RNASEQ STUDY OF PAIRED PATIENT EWING SARCOMA SPECIMENS
Filemon Dela Cruz
Favorite
(P 267) THE RAF/MEK INHIBITOR VS-6766 SHOWS EFFICACY IN RAS-MUTANT PEDIATRIC PRECLINICAL XENOGRAFT MODELS- A REPORT FROM THE PEDIATRIC PRECLINICAL IN VIVO TESTING CONSORTIUM
Filemon Dela Cruz
Favorite
Delclarro, Alessandro

Fondazione IRCCS Istituto Nazionale del Tumori
(P 309) RETROPERITONEAL LIPOMAS: MULTICENTER CLINICAL EXPERIENCE WITH AN EXTREMELY RARE DISEASE ENTITY
Alessandro Delclarro
Favorite
Delitto, Daniel

Stanford University
(P 37) DISSECTING THE TUMOR MICROENVIRONMENT OF UTERINE LEIOMYOSARCOMAS FOR TARGETED DRUG PREDICTIONS
Daniel Delitto
Favorite
DeMass, Reid

Medical University of South Carolina
(P 279) IMPACT OF PREOPERATIVE 5-DAY HYPOFRACTIONATED RADIOTHERAPY (HFRT) FOR SOFT TISSUE SARCOMA (STS) ON BARRIERS TO TREATMENT AT A HIGH-VOLUME SARCOMA CENTER (HV-SC)
Reid DeMass
Favorite
DeMatteo, Ronald

University of Pennsylvania
(P 185) CANCER TESTIS ANTIGENS AS TARGETS IN KIT11-MUTATED, IMATINIB-RESISTANT GIST
Ronald DeMatteo
Favorite
Demetri, George D.

Dana-Farber Cancer Institute
(P 194) UPDATED RESULTS FROM STRATEGIST 1: A PHASE 1/1B STUDY OF IDRX-42 (GSK6042981A) IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST)
George D. Demetri
Favorite
(P 416) A PHASE 2 MULTICENTER OPEN-LABEL BASKET STUDY OF TAZEMETOSTAT IN ADULT PATIENTS WITH INI1-NEGATIVE EPITHELIOID SARCOMA – FINAL ANALYSIS
George D. Demetri
Favorite
(P 434) A FIRST-IN-HUMAN PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF M3554, A NOVEL ANTI-GD2 ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS
George D. Demetri
Favorite
(P 464) EFFICACY OUTCOMES AMONG PATIENTS WITH ADVANCED EPITHELIOID SARCOMAS OF PROXIMAL-TYPE AND DISTAL-TYPE TREATED WITH TAZ: POST HOC ANALYSIS OF STUDY EZH-202
George D. Demetri
Favorite
Demicco, Elizabeth

Mount Sinai Hospital
(P 466) PATHOGENESIS AND THERAPEUTIC TARGETS IN KERATIN-POSITIVE GIANT CELL-RICH TUMOR
Elizabeth Demicco
Favorite
Demma, Jonathan Abraham

Surgical Department, Sharett Institute for Oncology, Hadassah Medical Center & Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
(P 06) RAPID, POINT-OF-CARE DNA METHYLATION & MOLECULAR LANDSCAPE BASED SARCOMA CLASSIFICATION
Jonathan Abraham Demma
Favorite
Denny, Carina

1.University of Miami, Miller School of Medicine, Department of Orthopedic Surgery
(P 31) TARGETING CANCER STEM CELLS BY TYROSINE PEPTIDE ANALOGUE IN REFRACTORY SARCOMA
Carina Denny
Favorite
Denton, Zachary

University of Kansas School of Medicine
(P 359) EVALUATION OF PREOPERATIVE MYXOFIBROSARCOMA GROWTH AND SURGICAL MORBIDITY AFTER NEOADJUVANT RADIATION USING SEMI-AUTOMATED VOLUMETRIC ANALYSIS
Zachary Denton
Favorite
(P 382) METHOD FOR VOLUMETRIC ASSESMENT OF TUMOR RESPONSE FOLLOWING NEOADJUVANT RADIATION IN PRIMARY MYXOFIBROSARCOMA
Zachary Denton
Favorite
Denu, Ryan

MD Anderson Cancer Center
(P 184) MTAP IN GASTROINTESTINAL STROMAL TUMOR (GIST): RATE OF MTAP LOSS AND CONCORDANCE BETWEEN GENOMIC SEQUENCING AND IMMUNOHISTOCHEMISTRY
Ryan Denu
Favorite
(P 391) ATRX LOSS BLOCKS THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS AND ADVANCES UNDIFFERENTIATED SARCOMA DEVELOPMENT
Ryan Denu
Favorite
(P 411) TFCP2 FUSION-POSITVE RHABDOMYOSARCOMAS: A REPORT OF 10 CASES AND A REVIEW OF THE LITERATURE
Ryan Denu
Favorite
DeRenzo, Chris

St. Jude Children's Research Hospital
(P 241) MACROPHAGE INHIBITION ENHANCES PERIPHERAL CAR T CELL EXPANSION AND TUMOR CONTROL IN A PATIENT-DERIVED HUMANIZED MODEL OF AUTOLOGOUS CAR T CELL EFFICACY IN PEDIATRIC OSTEOSARCOMA (OS)
Chris DeRenzo
Favorite
Dermawan, Josephine

Cleveland Clinic
(P 284) THE IMPACT OF SARCOMA SBRT ON THE IMMUNE SYSTEM: EARLY RESULTS FROM A PROSPECTIVE TRIAL
Josephine Dermawan
Favorite
Derrac Soria, Alicia

Adaptimmune
(P 247) SINGLE-CELL RNA SEQUENCING OF AFAMITRESGENE AUTOLEUCEL INDICATES MECHANISMS OF PERSISTENCE AND ANTI-TUMOR ACTIVITY
Alicia Derrac Soria
Favorite
Desai, Anant

Queen Elizabeth Hospital Birmingham
(P 307) STRATEGIES FOR DATA QUALITY IN TARPSWG RETROPERITONEAL SARCOMA REGISTRY (RESAR)
Anant Desai
Favorite
Deshpande, Hari

Yale School of Medicine
(P 128) ISOCITRATE DEHYDROGENASE 1 (IDH1) MUTATION TESTING IN THE PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA (CHONQUER)
Hari Deshpande
Favorite
(P 423) ZIFTOMENIB IN COMBINATION WITH IMATINIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) AFTER IMATINIB FAILURE: PHASE 1A/B STUDY OF SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY
Hari Deshpande
Favorite
Deshpande, Prashant

Sultan Qaboos Comprehensive Cancer Care and Research Center - University Medical City
(P 56) COMPARISON OF PATHOGENIC AND LIKELY PATHOGENIC VARIANTS DISTINCT FROM SPECIFIC DRIVERS IN DIFFERENT SARCOMA GROUPS
Prashant Deshpande
Favorite
Desir-Camille, Rheona

Memorial Sloan Kettering Cancer Center
(P 467) TREATMENT OUTCOMES IN AGGRESSIVE ANGIOMYXOMA: A SINGLE INSTITUTION EXPERIENCE
Rheona Desir-Camille
Favorite
Dessenberger, Joshua

University of Kansas Medical Center
(P 366) WOUND COMPLICATIONS AFTER ULTRA-HYPOFRACTIONATED NEOADJUVANT RADIATION FOR SOFT TISSUE SARCOMA: WHAT IS OPTIMAL SURGICAL TIMING?
Joshua Dessenberger
Favorite
Devaud, Nicolás A.

Clínica Universidad de Los Andes
(P 306) PROGNOSTIC NUTRITIONAL INDEX PREDICTS MAJOR POSTOPERATIVE COMPLICATIONS IN RETROPERITONEAL SARCOMA: RESULTS FROM THE LATAMSARC COHORT
Nicolás A. Devaud
Favorite
Dey, Mritunjoy

Maria Sklodowska-Curie National Research Institute of Oncology
(P 134) INTEGRATIVE MICRORNA PROFILING IN CHONDROSARCOMA: TOWARD BIOMARKER DISCOVERY AND PROGNOSTIC SIGNATURE DEVELOPMENT
Mritunjoy Dey
Favorite
Dhamija, Ekta

All India Institute of Medical Sciences, Delhi, India
(P 276) RADIATION-INDUCED SARCOMA (RIS): CLINICAL SPECTRUM AND ONCOLOGIC OUTCOMES FROM A TERTIARY INDIAN SARCOMA CLINIC
Ekta Dhamija
Favorite
(P 468) CLINICAL UTILITY OF TARGETED NEXT-GENERATION SEQUENCING IN GUIDING SARCOMA DIAGNOSIS AND PERSONALIZED MANAGEMENT: A SINGLE-CENTER STUDY FROM INDIA
Ekta Dhamija
Favorite
Dharmani, Charles

Daiichi Sankyo, Inc., Basking Ridge, NJ, USA
(P 336) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 5-YEAR RETROSPECTIVE HEPATIC SAFETY ASSESSMENT
Charles Dharmani
Favorite
(P 381) KNOWLEDGE, ATTITUDES, AND BEHAVIOR OF HEALTHCARE PROVIDERS ENROLLED IN THE PEXIDARTINIB RISK MITIGATION AND EVALUATION PROGRAM
Charles Dharmani
Favorite
Dharmashaktu, Yamini

All India Institute of Medical Sciences, New Delhi
(P 276) RADIATION-INDUCED SARCOMA (RIS): CLINICAL SPECTRUM AND ONCOLOGIC OUTCOMES FROM A TERTIARY INDIAN SARCOMA CLINIC
Yamini Dharmashaktu
Favorite
Dhir, Aditi

University of Miami/Jackson Memorial Hospital
(P 224) PAN-SARCOMA DATABASE (PSDB): AN UPDATE ON MIAMI'S COLLABORATIVE MULTI-USER DATA PIPELINE OF SARCOMA DATA USING REDCAP AND R CODING
Aditi Dhir
Favorite
(P 254) EOSINOPHILIC FASCIITIS (EF) AS A COMPLICATION OF NATURAL KILLER (NK) CELL-BASED IMMUNOTHERAPY IN A YOUNG ADULT WITH RECURRENT METASTATIC EWING SARCOMA
Aditi Dhir
Favorite
Di Blasi, Elena

Fondazione IRCCS Istituto Nazionale Tumori
(P 308) IMPACT OF PSOAS MUSCLE RESECTION ON OUTCOMES IN PRIMARY RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Elena Di Blasi
Favorite
(P 331) MAINTENANCE THERAPY (M-TP) WITH DACARBAZINE (DTIC) AFTER FIRST-LINE ANTHRACYCLINE-BASED DOUBLET IN ADVANCED LEIOMYOSARCOMA (LMS) PATIENTS (PTS): OUTCOMES OF A CASE SERIES IN A SINGLE REFERRAL CENTER
Elena Di Blasi
Favorite
Di Gioia, Dorit

Department of Medicine III, LMU University Hospital, Munich, Germany
(P 64) ATRX EXPRESSION CORRELATES WITH REDUCED IMMUNE CHECKPOINT EXPRESSION AND POOR SURVIVAL IN HIGH-RISK SOFT TISSUE SARCOMAS
Dorit Di Gioia
Favorite
(P 437) CLINICAL DATA CONFIRM GALENIC PRINCIPLE AND DEMONSTRATE THERAPEUTIC POTENTIAL OF THE001 (DPPG2-TSL-DOX) PLUS REGIONAL HYPERTHERMIA IN SOFT TISSUE SARCOMA
Dorit Di Gioia
Favorite
(P 443) FIRST-LINE PAZOPANIB IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS
Dorit Di Gioia
Favorite
Di Marzo, Massimiliano

Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale"
(P 328) INNOVATING SARCOMA EDUCATION: EARLY OUTCOMES OF THE ITALIAN SOCIETY OF SURGICAL ONCOLOGY (SICO) SARCOMA SOCIAL MULTI-PLATFORM JOURNAL CLUB INITIATIVE
Massimiliano Di Marzo
Favorite
Di Mauro, Pierluigi

Fondazione IRCSS Istituto Nazionale Tumori
(P 458) BETWEEN LYMPHOMAS AND SARCOMAS: A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG) ON HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN)
Pierluigi Di Mauro
Favorite
Diao, Yarui

Duke University
(P 126) SINGLE-CELL RNA SEQUENCING AND PROTEOMIC SPATIAL PROFILING REVEAL COMPLEX TUMOR MICROENVIRONMENT AND NOVEL IMMUNE INTERACTIONS IN CHONDROSARCOMA
Yarui Diao
Favorite
DIAZ LOPEZ, SEBASTIAN

HOSPITAL VIRGEN DE VALME
(P 321) COMPARATIVE ANALYSIS OF FIRST-LINE DOXORUBICIN-BASED COMBINATION REGIMENS IN METASTATIC LEIOMYOSARCOMA: IMPACT ON SURVIVAL AND DISEASE CONTROL
SEBASTIAN DIAZ LOPEZ
Favorite
Diaz-Montero, Claudia Marcela

Cleveland Clinic
(P 284) THE IMPACT OF SARCOMA SBRT ON THE IMMUNE SYSTEM: EARLY RESULTS FROM A PROSPECTIVE TRIAL
Claudia Marcela Diaz-Montero
Favorite
Dickson, Mark

Memorial Sloan Kettering Cancer Center
(P 187) THERAPEUTIC OUTCOMES IN NF1-ALTERED GIST TREATED WITH MEK INHIBITION: A SINGLE-CENTER EXPERIENCE
Mark Dickson
Favorite
(P 409) RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS INCLUDING HLA GENOTYPE IN MYXOID LIPOSARCOMA
Mark Dickson
Favorite
(P 467) TREATMENT OUTCOMES IN AGGRESSIVE ANGIOMYXOMA: A SINGLE INSTITUTION EXPERIENCE
Mark Dickson
Favorite
Diergaarde, Brenda

UPMC Hillman Cancer Center
(P 63) EVALUATING SURGICAL MARGINS IN SARCOMA RESECTION WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Brenda Diergaarde
Favorite
Dierselhuis, Miranda

Prinses Máxima Centrum
(P 417) EFFICACY AND SAFETY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS
Miranda Dierselhuis
Favorite
Dietrich, Daniel

Swiss Group of Clinical Cancer Research
(P 436) SAKK 57/24 FEASIBILITY OF TOTAL NEOADJUVANT TREATMENT WITH HYPERTHERMIA IN PATIENTS WITH HIGH-RISK EXTREMITY AND TRUNK SOFT TISSUE SARCOMA. A MULTICENTER, SINGLE ARM, OPEN LABEL, PHASE II TRIAL
Daniel Dietrich
Favorite
Dijkstra, Sander

LUMC
(P 144) THE RISK OF PATHOLOGICAL FRACTURES AFTER INTRALESIONAL CURETTAGE IN ATYPICAL CARTILAGINOUS TUMOURS: A RETROSPECTIVE COHORT STUDY
Sander Dijkstra
Favorite
Dileo, Palma

IRCCS Istituto Ortopedico Rizzoli
(P 416) A PHASE 2 MULTICENTER OPEN-LABEL BASKET STUDY OF TAZEMETOSTAT IN ADULT PATIENTS WITH INI1-NEGATIVE EPITHELIOID SARCOMA – FINAL ANALYSIS
Palma Dileo
Favorite
Dilley, Julian

University of Florida
(P 269) INCIDENCE OF MALIGNANCY IN BIOPSIED PEDIATRIC SOFT TISSUE MASSES
Julian Dilley
Favorite
(P 272) THE HAZARDS OF BIOPSY IN PEDIATRIC SOFT TISSUE SARCOMAS
Julian Dilley
Favorite
Dinart, Derek

Institut Bergonié
(P 324) FULLY MATURE TERTIARY LYMHOID STRUCTURES AS PREDICTORS OF LOCAL RECURRENCE IN SOFT TISSUE SARCOMAS
Derek Dinart
Favorite
Dinerman, Aaron

NCI/NIH
(P 181) THE DEVELOPMENT OF A NOVEL PDGFRA RESISTANCE MUTATION IN A RECURRENT KIT-MUTANT GASTROINTESTINAL STROMAL TUMOR (GIST)
Aaron Dinerman
Favorite
Dingle, Ezekiel

David Geffen School of Medicine at University of California Los Angeles
(P 16) MITOCHONDRIAL GENETIC VARIATION ORCHESTRATES COPZ1 TRANSCRIPT HETEROGENEITY AND REVEALS TELOMERE-MEDIATED VULNERABILITIES IN OSTEOSARCOMA
Ezekiel Dingle
Favorite
(P 72) COUNTY-LEVEL ASSOCIATIONS BETWEEN AIRBORNE TOXICANT EMISSIONS AND EWING SARCOMA DIAGNOSIS IN THE UNITED STATES
Ezekiel Dingle
Favorite
(P 81) ASSESSING PROGNOSTIC FACTORS OF CAUSE-SPECIFIC SURVIVAL IN PATIENTS WITH MALIGNANT GIANT CELL TUMORS: A POPULATION BASED STUDY FROM THE SEER DATABASE
Ezekiel Dingle
Favorite
(P 92) PRIMARY TUMOR SIZE AS AN INDEPENDENT PROGNOSTIC FACTOR IN OSTEOSARCOMA: PROPENSITY SCORE-MATCHED ANALYSIS DEMONSTRATES A CONTINUOUS DOSE-RESPONSE RELATIONSHIP
Ezekiel Dingle
Favorite
(P 107) IS THERE A BETTER OPTION: INTRAMEDULLARY NAIL VERSUS PLATE OSTEOSYNTHESIS FOR PATHOLOGIC HUMERAL FRACTURES?
Ezekiel Dingle
Favorite
(P 108) DISTANCE WEIGHTED MATCHING IN THE QUANTIFICATION OF EXCESS MORBIDITY IN EXTERNAL HEMIPELVECTOMY AND HIP DISARTICULATION
Ezekiel Dingle
Favorite
(P 157) INCOME IMPACTS OVERALL BUT NOT CAUSE-SPECIFIC SURVIVAL IN PATIENTS WITH CHONDROSARCOMA: A POPULATION BASED STUDY FROM THE SEER DATABASE
Ezekiel Dingle
Favorite
(P 232) IS THERE A ROLE FOR POSITRON EMISSION TOMOGRAPHY IN THE STAGING OF LANGERHANS CELL HISTIOCYTOSIS?
Ezekiel Dingle
Favorite
(P 384) PELVIC LOCATION PREDICTS WORSE OUTCOMES IN ALVEOLAR RHABDOMYOSARCOMA: UNDERUSE OF RADIOTHERAPY AND MISSED SURVIVAL BENEFIT
Ezekiel Dingle
Favorite
Diniz, Paulo

Hospital das Clínicas da Universidade Federal de Minas Gerais
(P 128) ISOCITRATE DEHYDROGENASE 1 (IDH1) MUTATION TESTING IN THE PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA (CHONQUER)
Paulo Diniz
Favorite
Distel, Luitpold

Department of Radiation Oncology, Universitätsstraße 27, 91054 Erlangen, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany
(P 288) IDENTIFICATION OF A DNA REPAIR INHIBITOR FOR THE COMBINATION WITH LURBINECTEDIN AND RADIOTHERAPY IN SARCOMA CELL LINES
Luitpold Distel
Favorite
Divirgilio, Rebecca

Dana-Farber Cancer Institute
(P 427) PHASE 1/2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF PEEL-224 IN COMBINATION WITH VINCRISTINE AND TEMOZOLOMIDE IN ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SARCOMAS
Rebecca Divirgilio
Favorite
Doherty, Mark

St. Vincent's UCD Cancer Centre
(P 211) HEALTH-RELATED QUALITY OF LIFE IN IRISH SARCOMA PATIENTS
Mark Doherty
Favorite
(P 213) FINANCIAL TOXICITY IN IRISH SARCOMA CARE: A SINGLE-CENTRE ANALYSIS
Mark Doherty
Favorite
Doherty, Terence

Dept. of Surgery, Moores Cancer Center, University of California San Diego
(P 197) DIFFERENTIAL EFFECTS OF ANAGRELIDE IN GASTROINTESTINAL STROMAL TUMORS (GIST) IN VITRO
Terence Doherty
Favorite
Doldi, Valentina

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 32) EFFECTIVENESS OF LURBINECTEDIN PLUS IRINOTECAN IN PRECLINICAL MODEL OF DESMOPLASTIC SMALL ROUND CELL TUMOR
Valentina Doldi
Favorite
Dolman, Emmy

Children's Cancer Institute
(P 266) TARGETING THE DNA DAMAGE RESPONSE TO ADVANCE PRECISION THERAPIES IN PAEDIATRIC SARCOMA
Emmy Dolman
Favorite
Donaldson, Ian

Adaptimmune
(P 247) SINGLE-CELL RNA SEQUENCING OF AFAMITRESGENE AUTOLEUCEL INDICATES MECHANISMS OF PERSISTENCE AND ANTI-TUMOR ACTIVITY
Ian Donaldson
Favorite
Donaldson, Nathan

University of Colorado Department of Orthopedics
(P 268) QUALITY OF LIFE OUTCOMES IN PEDIATRIC PATIENTS UNDERGOING SURGICAL INTERVENTION FOR LOWER EXTREMITY BONE SARCOMAS
Nathan Donaldson
Favorite
Dona, Margo

Institute of Biology Leiden, Leiden University
(P 197) DIFFERENTIAL EFFECTS OF ANAGRELIDE IN GASTROINTESTINAL STROMAL TUMORS (GIST) IN VITRO
Margo Dona
Favorite
Donati, Davide Maria

IRCCS Rizzoli Orthopaedic Institute
(P 18) ESTABLISHMENT AND CHARACTERIZATION OF A NOVEL PRIMARY CELL LINE FROM A BONE METASTASIS OF OSTEOSARCOMA
Davide Maria Donati
Favorite
Dong, Haoyao

Department of Anesthesiology, Peking University International Hospital
(P 305) COMPARISON OF GOAL-DIRECTED VERSUS EMPIRICAL TRANSFUSION MANAGEMENT IN PATIENTS WITH SEVERE HEMORRHAGE DURING RETROPERITONEAL TUMOR SURGERY
Haoyao Dong
Favorite
(P 469) THE IMPACT OF PREOPERATIVE ANEMIA ON POSTOPERATIVE COMPLICATIONS AND SHORT-TERM PROGNOSIS IN RETROPERITONEAL TUMOR SURGERY PATIENTS.
Haoyao Dong
Favorite
dongyang, ma

The Second Hospital of HeBei Medical University
(P 469) THE IMPACT OF PREOPERATIVE ANEMIA ON POSTOPERATIVE COMPLICATIONS AND SHORT-TERM PROGNOSIS IN RETROPERITONEAL TUMOR SURGERY PATIENTS.
ma dongyang
Favorite
Donoghue, Mark

Memorial Sloan Kettering Cancer Center
(P 409) RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS INCLUDING HLA GENOTYPE IN MYXOID LIPOSARCOMA
Mark Donoghue
Favorite
Dorleijn, Desirée

Uz Ghent
(P 144) THE RISK OF PATHOLOGICAL FRACTURES AFTER INTRALESIONAL CURETTAGE IN ATYPICAL CARTILAGINOUS TUMOURS: A RETROSPECTIVE COHORT STUDY
Desirée Dorleijn
Favorite
Doshi, Dipam

Springworks Therapeutics, Inc.
(P 357) DEVELOPMENT OF AN ALGORITHM TO IDENTIFY PATIENTS (PT) WITH DESMOID TUMORS (DT) IN A UNITED STATES (US) CLAIMS DATASET
Dipam Doshi
Favorite
(P 364) TRENDS IN SURGICAL MANAGEMENT OF DESMOID TUMOR IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Dipam Doshi
Favorite
Dotterweich, Julia

Merck Healthcare KGaA
(P 42) PRECLINICAL VALIDATION OF M3554, A NOVEL ANTI-GD2 ANTIBODY-DRUG CONJUGATE, AND EPIGENETIC SENSITIZATION STRATEGIES IN SOFT TISSUE SARCOMAS
Julia Dotterweich
Favorite
Dou, Juan

Emory University
(P 21) EXAMINING THE THERAPEUTIC EFFECT OF TBL1/ β-CATENIN TARGETED COMBINATION THERAPIES ON METASTATIC OSTEOSARCOMA
Juan Dou
Favorite
Doung, Yee-Cheen

Oregon Health & Science University
(P 93) INTERCALARY COMPRESSIVE OSSEOINTEGRATION OF DIAPHYSEAL TUMORS: A MULTI-INSTITUTIONAL CASE SERIES
Yee-Cheen Doung
Favorite
(P 364) TRENDS IN SURGICAL MANAGEMENT OF DESMOID TUMOR IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Yee-Cheen Doung
Favorite
Dreher, Rachel

Nationwide Children's Hospital
(P 23) DEFINING THE NONENZYMATIC FUNCTIONS OF LSD1 IN EWING SARCOMA
Rachel Dreher
Favorite
Drilon, Alexander

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
(P 417) EFFICACY AND SAFETY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS
Alexander Drilon
Favorite
Druta, Mihaela

Moffitt Cancer Center
(P 247) SINGLE-CELL RNA SEQUENCING OF AFAMITRESGENE AUTOLEUCEL INDICATES MECHANISMS OF PERSISTENCE AND ANTI-TUMOR ACTIVITY
Mihaela Druta
Favorite
(P 394) DUAL OR TRIMODALITY THERAPY VERSUS SURGERY ALONE IN RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST
Mihaela Druta
Favorite
(P 453) OUTCOMES OF PLEOMORPHIC LIPOSARCOMA PATIENTS FOLLOWING MULTI-DISCIPLINARY MANAGEMENT WITHIN A TERTIARY CANCER CENTER
Mihaela Druta
Favorite
DUAN, ZHENFENG

University of Miami
(P 117) THERAPEUTIC POTENTIAL OF DOXORUBICIN AND DASATINIB COMBINATION IN OSTEOSARCOMA
ZHENFENG DUAN
Favorite
(P 131) GLUCOSE TRANSPORTER 1 (GLUT1) INHIBITION DECREASES THE GROWTH AND PROLIFERATION OF CHONDROSARCOMA
ZHENFENG DUAN
Favorite
(P 225) GLOBAL REGISTRY OF SOLITARY FIBROUS TUMORS (SFT): INTEGRATING CLINICAL, MOLECULAR, AND ENVIRONMENTAL DATA- THE HOROWITZ SFT INITIATIVE (HSFTI)
ZHENFENG DUAN
Favorite
DuBois, Steven

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
(P 168) LEVERAGING LARGE LANGUAGE MODELS FOR STRUCTURED INFORMATION EXTRACTION FROM EWING SARCOMA PATHOLOGY REPORTS
Steven DuBois
Favorite
(P 417) EFFICACY AND SAFETY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS
Steven DuBois
Favorite
(P 427) PHASE 1/2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF PEEL-224 IN COMBINATION WITH VINCRISTINE AND TEMOZOLOMIDE IN ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SARCOMAS
Steven DuBois
Favorite
Dufour, Antoine

Arnie Charbonneau Cancer Institute and McCaig Institute for Bone and Joint Health
(P 238) INVESTIGATING HOW MACROPHAGES INFILTRATE THE TUMOUR MICROENVIRONMENT AND INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF STS
Antoine Dufour
Favorite
(P 378) HIGH DOSE RADIATION THERAPY PROMOTES IMMUNE SUPPRESSIVE MACROPHAGE PHENOTYPES, WHEREAS LOW DOSE RADIATION THERAPY PROMOTES IMMUNOGENIC MACROPHAGE PHENOTYPES IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Antoine Dufour
Favorite
Dunphy, Mallory

Meharry Medical College
(P 310) ATYPICAL SPINDLE CELL PLEOMORPHIC LIPOMATOUS TUMORS OF THE RETROPERITONEUM ARE HETEROGENOUS: A REPORT OF FOUR DISPARATE CASES
Mallory Dunphy
Favorite
Dupont, Christopher

Adaptimmune
(P 247) SINGLE-CELL RNA SEQUENCING OF AFAMITRESGENE AUTOLEUCEL INDICATES MECHANISMS OF PERSISTENCE AND ANTI-TUMOR ACTIVITY
Christopher Dupont
Favorite
Duprée, Anna

Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
(P 441) COLOSARC-Q: A PROSPECTIVE MULTICENTER STUDY FOR EVALUATING SURGICAL STRATEGIES FOR COLORECTAL RESECTIONS AND POSTOPERATIVE QUALITY OF LIFE IN RETROPERITONEAL SARCOMA PATIENTS
Anna Duprée
Favorite
Duran Sierra, Elvis de Jesus

The University of Texas MD Anderson Cancer Center
(P 311) A FOLLOW-UP STUDY ON THE NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING FOR EXTREMITY DESMOID FIBROMATOSIS RESPONSE ASSESSMENT
Elvis de Jesus Duran Sierra
Favorite
(P 317) BUILDING A PRE-SURGICAL MULTIPARAMETRIC-MRI-BASED PREDICTIVE TREATMENT RESPONSE MODEL FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA TO REPLACE RECIST
Elvis de Jesus Duran Sierra
Favorite
(P 334) MRI VOLUMETRIC AND MODIFIED CHOI-BASED ASSESSMENT OF TREATMENT RESPONSE IN EXTREMITY DESMOID TUMORS TREATED WITH NIROGACESTAT OR SORAFENIB
Elvis de Jesus Duran Sierra
Favorite
(P 406) PILOT STUDY: CAN A MULTIPARAMETRIC MRI-DERIVED MODEL OUTPERFORM RECIST PREDICTING PATHOLOGY RESPONSE IN RHABDOMYOSARCOMA?
Elvis de Jesus Duran Sierra
Favorite
(P 420) THE EFFECT OF CHEMOTHERAPY AND RADIOTHERAPY IN THE MULTIPARAMETRIC MRI-BASED ASSESSMENT OF TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Elvis de Jesus Duran Sierra
Favorite
Durmaz, Arda

Cleveland Clinic
(P 10) COLLATERAL SENSITIVIES EMERGE DURING THE EVOLUTION OF CHEMORESISTANCE TO MAP CHEMOTHERAPY IN OSTEOSARCOMA
Arda Durmaz
Favorite
Dusch, Martin

Pain Centre, Department of Anesthesiology and Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University
(P 312) APOSST: A PROSPECTIVE TRIAL TO EVALUATE ACUPUNCTURE AFTER SURGERY OF EXTREMITY SOFT TISSUE TUMORS
Martin Dusch
Favorite
Dutour, Aurelie

Léon Bérard Centre
(P 139) IMMUNOGENOMIC PROFILING OF CHONDROSARCOMA REVEALS DISTINCT IMMUNE PHENOTYPES AND PROGNOSTIC MUTATIONS
Aurelie Dutour
Favorite
Dutta, Ananya

Duke University’
(P 125) TARGETING LCP1-MEDIATED METASTASIS IN CHONDROSARCOMA WITH OROXYLIN A
Ananya Dutta
Favorite
Dybel, Stacey

Department of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School
(P 45) MONITORING EWSR1 FUSIONS IN SARCOMA PATIENTS USING PERSONALIZED LIQUID BIOPSY ASSAYS
Stacey Dybel
Favorite
Dyer, Michael

St. Jude Children's Research Hospital
(P 267) THE RAF/MEK INHIBITOR VS-6766 SHOWS EFFICACY IN RAS-MUTANT PEDIATRIC PRECLINICAL XENOGRAFT MODELS- A REPORT FROM THE PEDIATRIC PRECLINICAL IN VIVO TESTING CONSORTIUM
Michael Dyer
Favorite